Market Study on Anti-VEGF: Close to Half of the Market Share Accounted for by Vascular Endothelial Growth Factor-A inhibitors

The latest publication by Persistence Market Research on the global anti-VEGF market evaluates the opportunities and current market landscape and provides detailed analysis, and updates about corresponding sections affecting the market. The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2023 to 2033.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for anti-VEGF products and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the anti-VEGF market. Shareholders in the anti-VEGF market, industry experts, investors, researchers, and reporters, as well as business enthusiasts can leverage insights and information presented in this Persistence Market Research study.

Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the anti-VEGF market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research's study on the anti-VEGF market offers information divided into five important segments - drug, type, disease indication, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Drug

Small Molecules

Pazopanib

Sunitinib

Sorafenib

Regorafenib

Cabozantinib

Lenvatinib

Ponatinib

Cabozantinib

Axitinib

tivozanib

Vandetanib

Anlotinib

Apatinib

Fruquintinib

Surufatinib

Biologics

Bevacizumab

Aflibercept

Ramucirumab

Type

VEGF A Inhibitors

VEGF B Inhibitors

VEGF C Inhibitors

Placenta Growth Factor Inhibitors

Disease Indication

Oncology

Non-Small Cell Lung Cancer

Renal Cell Carcinoma

Colorectal Cancer

Hepatocellular Carcinoma

Cervical Cancer

Others

Hematology Disorders

Ophthalmology Disorders

Wet Age-Related Macular Degeneration (AMD)

Diabetic Retinopathy

Others

Distribution Channel

Hospitals

Specialty Clinics

Mail Order Pharmacies

Region

North America

Latin America

Europe

South Asia

East Asia

Oceania

Middle East and Africa (MEA)

Key Questions Answered in Report

Which regions will continue to remain the most profitable markets for anti-VEGF over the coming years?

How will changing trends influence the market?

How has the COVID-19 crisis influenced market growth?

How can market players capture the low-hanging opportunities in developed regions?

What are the strategies of stakeholders in the market to shape their position in this landscape?

What are the restraining factors that investors need to be aware of and might tackle while investing in the market?

What are the developmental trends that will influence the market?

How can companies in the anti-VEGF market avail themselves the growth opportunities in developed and emerging sectors?

Research Methodology

In Persistence Market Research's study, a unique research methodology is utilized to conduct extensive research on the growth of the anti-VEGF market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market, and makes Persistence Market Research's projections on the growth prospects of the anti-VEGF market are more accurate and reliable.

Product Code: PMRREP33422

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Regulatory Landscape
4.2. Pipeline Assessment
4.3. Product Adoption and Usage Analysis
4.4. Key Marketing & Promotional Strategies Adopted by Companies
4.5. PESTLE Analysis
4.6. Porters Analysis
4.7. Value Chain Analysis

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Spending Outlook
- 5.1.3. Global Oncology Therapeutic Medicines Market Outlook
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Increase in R&D Funding and Grants
- 5.2.2. Rising Research Activities for Rare Disease Indications
- 5.2.3. High Demand for Biologics
- 5.2.4. Surge in Research Collaborations for Development of Drugs
- 5.2.5. High Prevalence of Cancer
- 5.2.6. New Product Launch
- 5.2.7. Regulatory Approvals
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

6.1. COVID-19 and Impact Analysis
- 6.1.1. Revenue By Drug Types
- 6.1.2. Revenue By Types
- 6.1.3. Revenue By Disease Indication
- 6.1.4. Revenue By Distribution Channel
- 6.1.5. Revenue By Country
6.2. 2022 Market Scenario

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012-2022 and Forecast, 2023-2033

7.1. Historical Market Value (US$ Mn) Analysis, 2012-2022
7.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2012-2022 and Forecast 2023-2033, By Drug Types

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis, By Drug Types, 2012-2022
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Types, 2023-2033
- 8.3.1. Small Molecules
  - 8.3.1.1. Pazopanib
  - 8.3.1.2. Sunitinib
  - 8.3.1.3. Regorafenib
  - 8.3.1.4. Cabozantinib
  - 8.3.1.5. Lenvatinib
  - 8.3.1.6. Ponatinib
  - 8.3.1.7. Cabozantinib
  - 8.3.1.8. Axitinib
  - 8.3.1.9. Tivozanib
  - 8.3.1.10. Vandetanib
  - 8.3.1.11. Sorafenib
  - 8.3.1.12. Anlotinib
  - 8.3.1.13. Apatinib
  - 8.3.1.14. Fruquintinib
  - 8.3.1.15. Surufatinib
- 8.3.2. Biologics
  - 8.3.2.1. Bevacizumab
  - 8.3.2.2. Ziv-Aflibercept
  - 8.3.2.3. Ramucirumab
  - 8.3.2.4. Ranibizumab
8.4. Market Attractiveness Analysis By Drug Types

9. Global Market Analysis 2012-2022 and Forecast 2023-2033, By Types

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis, By Types, 2012-2022
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Types, 2023-2033
- 9.3.1. VEGF A Inhibitors
- 9.3.2. VEGF B Inhibitors
- 9.3.3. VEGF C Inhibitors
- 9.3.4. Placenta Growth Factor Inhibitors
9.4. Market Attractiveness Analysis By Types

10. Global Market Analysis 2012-2022 and Forecast 2023-2033, By Disease Indication

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis, By Disease Indication, 2012-2022
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Indication, 2023-2033
- 10.3.1. Oncology
  - 10.3.1.1. Cervical Cancer
  - 10.3.1.2. Non-Small Cell Lung Cancer
  - 10.3.1.3. Renal Cell Carcinoma
  - 10.3.1.4. Soft Tissue Sarcoma
  - 10.3.1.5. Colorectal Cancer
  - 10.3.1.6. Liver Cancer
  - 10.3.1.7. Others
- 10.3.2. Hematology Disorders
- 10.3.3. Ophthalmology Disorders
  - 10.3.3.1. Wet Age-Related Macular Degeneration (AMD)
  - 10.3.3.2. Diabetic Retinopathy
  - 10.3.3.3. Others
10.4. Market Attractiveness Analysis By Disease Indication

11. Global Market Analysis 2012-2022 and Forecast 2023-2033, By Distribution Channel

11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2012-2022
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023-2033
- 11.3.1. Hospitals
- 11.3.2. Specialty Clinics
- 11.3.3. Cancer Research Centers
- 11.3.4. Mail Order Pharmacies
11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Region

12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Region, 2012-2022
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2023-2033
- 12.3.1. North America
- 12.3.2. Latin America
- 12.3.3. Europe
- 12.3.4. East Asia
- 12.3.5. South Asia
- 12.3.6. Oceania
- 12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2012-2022 and Forecast 2023-2033

13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2022
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023-2033
- 13.3.1. By Country
  - 13.3.1.1. U.S.
  - 13.3.1.2. Canada
- 13.3.2. By Drug Types
- 13.3.3. By Types
- 13.3.4. By Disease Indication
- 13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Drug Types
- 13.4.3. By Types
- 13.4.4. By Disease Indication
- 13.4.5. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
- 13.8.1. U.S. Market Analysis
  - 13.8.1.1. Introduction
  - 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.1.2.1. By Drug Types
    - 13.8.1.2.2. By Types
    - 13.8.1.2.3. By Disease Indication
    - 13.8.1.2.4. By Distribution Channel
- 13.8.2. Canada Market Analysis
  - 13.8.2.1. Introduction
  - 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.2.2.1. By Drug Types
    - 13.8.2.2.2. By Types
    - 13.8.2.2.3. By Disease Indication
    - 13.8.2.2.4. By Distribution Channel

14. Latin America Market Analysis 2012-2022 and Forecast 2023-2033

14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2022
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023-2033
- 14.3.1. By Country
  - 14.3.1.1. Mexico
  - 14.3.1.2. Brazil
  - 14.3.1.3. Argentina
  - 14.3.1.4. Rest of Latin America
- 14.3.2. By Drug Types
- 14.3.3. By Types
- 14.3.4. By Disease Indication
- 14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Drug Types
- 14.4.3. By Types
- 14.4.4. By Disease Indication
- 14.4.5. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
- 14.8.1. Mexico Market Analysis
  - 14.8.1.1. Introduction
  - 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.1.2.1. By Drug Types
    - 14.8.1.2.2. By Types
    - 14.8.1.2.3. By Disease Indication
    - 14.8.1.2.4. By Distribution Channel
- 14.8.2. Brazil Market Analysis
  - 14.8.2.1. Introduction
  - 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.2.2.1. By Drug Types
    - 14.8.2.2.2. By Types
    - 14.8.2.2.3. By Disease Indication
    - 14.8.2.2.4. By Distribution Channel
- 14.8.3. Argentina Market Analysis
  - 14.8.3.1. Introduction
  - 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.3.2.1. By Drug Types
    - 14.8.3.2.2. By Types
    - 14.8.3.2.3. By Disease Indication
    - 14.8.3.2.4. By Distribution Channel

15. Europe Market Analysis 2012-2022 and Forecast 2023-2033

15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2022
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023-2033
- 15.3.1. By Country
  - 15.3.1.1. Germany
  - 15.3.1.2. Italy
  - 15.3.1.3. France
  - 15.3.1.4. U.K.
  - 15.3.1.5. Spain
  - 15.3.1.6. BENELUX
  - 15.3.1.7. Nordic Countries
  - 15.3.1.8. Russia
  - 15.3.1.9. Rest of Europe
- 15.3.2. By Drug Types
- 15.3.3. By Types
- 15.3.4. By Disease Indication
- 15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Drug Types
- 15.4.3. By Types
- 15.4.4. By Disease Indication
- 15.4.5. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
- 15.8.1. Germany Market Analysis
  - 15.8.1.1. Introduction
  - 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.1.2.1. By Drug Types
    - 15.8.1.2.2. By Types
    - 15.8.1.2.3. By Disease Indication
    - 15.8.1.2.4. By Distribution Channel
- 15.8.2. Italy Market Analysis
  - 15.8.2.1. Introduction
  - 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.2.2.1. By Drug Types
    - 15.8.2.2.2. By Types
    - 15.8.2.2.3. By Disease Indication
    - 15.8.2.2.4. By Distribution Channel
- 15.8.3. France Market Analysis
  - 15.8.3.1. Introduction
  - 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.3.2.1. By Drug Types
    - 15.8.3.2.2. By Types
    - 15.8.3.2.3. By Disease Indication
    - 15.8.3.2.4. By Distribution Channel
- 15.8.4. U.K. Market Analysis
  - 15.8.4.1. Introduction
  - 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.4.2.1. By Drug Types
    - 15.8.4.2.2. By Types
    - 15.8.4.2.3. By Disease Indication
    - 15.8.4.2.4. By Distribution Channel
- 15.8.5. Spain Market Analysis
  - 15.8.5.1. Introduction
  - 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.5.2.1. By Drug Types
    - 15.8.5.2.2. By Types
    - 15.8.5.2.3. By Disease Indication
    - 15.8.5.2.4. By Distribution Channel
- 15.8.6. BENELUX Market Analysis
  - 15.8.6.1. Introduction
  - 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.6.2.1. By Drug Types
    - 15.8.6.2.2. By Types
    - 15.8.6.2.3. By Disease Indication
    - 15.8.6.2.4. By Distribution Channel
- 15.8.7. Nordic Countries Market Analysis
  - 15.8.7.1. Introduction
  - 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.7.2.1. By Drug Types
    - 15.8.7.2.2. By Types
    - 15.8.7.2.3. By Disease Indication
    - 15.8.7.2.4. By Distribution Channel
- 15.8.8. Russia Market Analysis
  - 15.8.8.1. Introduction
  - 15.8.8.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.8.2.1. By Drug Types
    - 15.8.8.2.2. By Types
    - 15.8.8.2.3. By Disease Indication
    - 15.8.8.2.4. By Distribution Channel

16. East Asia Market Analysis 2012-2022 and Forecast 2023-2033

16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2022
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023-2033
- 16.3.1. By Country
  - 16.3.1.1. China
  - 16.3.1.2. Japan
  - 16.3.1.3. South Korea
- 16.3.2. By Drug Types
- 16.3.3. By Types
- 16.3.4. By Disease Indication
- 16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Drug Types
- 16.4.3. By Types
- 16.4.4. By Disease Indication
- 16.4.5. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
- 16.8.1. China Market Analysis
  - 16.8.1.1. Introduction
  - 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.1.2.1. By Drug Types
    - 16.8.1.2.2. By Types
    - 16.8.1.2.3. By Disease Indication
    - 16.8.1.2.4. By Distribution Channel
- 16.8.2. Japan Market Analysis
  - 16.8.2.1. Introduction
  - 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.2.2.1. By Drug Types
    - 16.8.2.2.2. By Types
    - 16.8.2.2.3. By Disease Indication
    - 16.8.2.2.4. By Distribution Channel
- 16.8.3. South Korea Market Analysis
  - 16.8.3.1. Introduction
  - 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.3.2.1. By Drug Types
    - 16.8.3.2.2. By Types
    - 16.8.3.2.3. By Disease Indication
    - 16.8.3.2.4. By Distribution Channel

17. South Asia Market Analysis 2012-2022 and Forecast 2023-2033

17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2022
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023-2033
- 17.3.1. By Country
  - 17.3.1.1. India
  - 17.3.1.2. Indonesia
  - 17.3.1.3. Malaysia
  - 17.3.1.4. Thailand
  - 17.3.1.5. Rest of South Asia
- 17.3.2. By Drug Types
- 17.3.3. By Types
- 17.3.4. By Disease Indication
- 17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Drug Types
- 17.4.3. By Types
- 17.4.4. By Disease Indication
- 17.4.5. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
- 17.8.1. India Market Analysis
  - 17.8.1.1. Introduction
  - 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.1.2.1. By Drug Types
    - 17.8.1.2.2. By Types
    - 17.8.1.2.3. By Disease Indication
    - 17.8.1.2.4. By Distribution Channel
- 17.8.2. Indonesia Market Analysis
  - 17.8.2.1. Introduction
  - 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.2.2.1. By Drug Types
    - 17.8.2.2.2. By Types
    - 17.8.2.2.3. By Disease Indication
    - 17.8.2.2.4. By Distribution Channel
- 17.8.3. Malaysia Market Analysis
  - 17.8.3.1. Introduction
  - 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.3.2.1. By Drug Types
    - 17.8.3.2.2. By Types
    - 17.8.3.2.3. By Disease Indication
    - 17.8.3.2.4. By Distribution Channel
- 17.8.4. Thailand Market Analysis
  - 17.8.4.1. Introduction
  - 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.4.2.1. By Drug Types
    - 17.8.4.2.2. By Types
    - 17.8.4.2.3. By Disease Indication
    - 17.8.4.2.4. By Distribution Channel

18. Oceania Market 2012-2022 and Forecast 2023-2033

18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2022
18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023-2033
- 18.3.1. By Country
  - 18.3.1.1. Australia
  - 18.3.1.2. New Zealand
- 18.3.2. By Drug Types
- 18.3.3. By Types
- 18.3.4. By Disease Indication
- 18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By Drug Types
- 18.4.3. By Types
- 18.4.4. By Disease Indication
- 18.4.5. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
- 18.8.1. Australia Market Analysis
  - 18.8.1.1. Introduction
  - 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.1.2.1. By Drug Types
    - 18.8.1.2.2. By Types
    - 18.8.1.2.3. By Disease Indication
    - 18.8.1.2.4. By Distribution Channel
- 18.8.2. New Zealand Market Analysis
  - 18.8.2.1. Introduction
  - 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.2.2.1. By Drug Types
    - 18.8.2.2.2. By Types
    - 18.8.2.2.3. By Disease Indication
    - 18.8.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Market Analysis 2012-2022 and Forecast 2023-2033

19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2022
19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023-2033
- 19.3.1. By Country
  - 19.3.1.1. GCC Countries
  - 19.3.1.2. Turkiye
  - 19.3.1.3. South Africa
  - 19.3.1.4. North Africa
  - 19.3.1.5. Rest of Middle East and Africa
- 19.3.2. By Drug Types
- 19.3.3. By Types
- 19.3.4. By Disease Indication
- 19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
- 19.4.1. By Country
- 19.4.2. By Drug Types
- 19.4.3. By Types
- 19.4.4. By Disease Indication
- 19.4.5. By Distribution Channel
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
- 19.8.1. GCC Countries Market Analysis
  - 19.8.1.1. Introduction
  - 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.1.2.1. By Drug Types
    - 19.8.1.2.2. By Types
    - 19.8.1.2.3. By Disease Indication
    - 19.8.1.2.4. By Distribution Channel
- 19.8.2. Turkiye Anti-VEGF Market Analysis
  - 19.8.2.1. Introduction
  - 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.2.2.1. By Drug Types
    - 19.8.2.2.2. By Types
    - 19.8.2.2.3. By Disease Indication
    - 19.8.2.2.4. By Distribution Channel
- 19.8.3. South Africa Market Analysis
  - 19.8.3.1. Introduction
  - 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.3.2.1. By Drug Types
    - 19.8.3.2.2. By Types
    - 19.8.3.2.3. By Disease Indication
    - 19.8.3.2.4. By Distribution Channel
- 19.8.4. North Africa Market Analysis
  - 19.8.4.1. Introduction
  - 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.4.2.1. By Drug Types
    - 19.8.4.2.2. By Types
    - 19.8.4.2.3. By Disease Indication
    - 19.8.4.2.4. By Distribution Channel

20. Market Structure Analysis

20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Concentration
20.4. Market Presence Analysis
- 20.4.1. Regional Footprint Analysis
- 20.4.2. Channel Footprint Analysis

21. Competition Analysis

21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
- 21.3.1. Pfizer Inc.
  - 21.3.1.1. Overview
  - 21.3.1.2. Product Portfolio
  - 21.3.1.3. Sales Footprint
  - 21.3.1.4. Key Financial
  - 21.3.1.5. Key Developments
  - 21.3.1.6. SWOT Analysis
  - 21.3.1.7. Strategy Overview
    - 21.3.1.7.1. Marketing Strategies
    - 21.3.1.7.2. Channel Strategies
- 21.3.2. Bayer AG
  - 21.3.2.1. Overview
  - 21.3.2.2. Product Portfolio
  - 21.3.2.3. Sales Footprint
  - 21.3.2.4. Key Financial
  - 21.3.2.5. Key Developments
  - 21.3.2.6. SWOT Analysis
  - 21.3.2.7. Strategy Overview
    - 21.3.2.7.1. Marketing Strategies
    - 21.3.2.7.2. Channel Strategies
- 21.3.3. Novartis AG
  - 21.3.3.1. Overview
  - 21.3.3.2. Product Portfolio
  - 21.3.3.3. Sales Footprint
  - 21.3.3.4. Key Financial
  - 21.3.3.5. Key Developments
  - 21.3.3.6. SWOT Analysis
  - 21.3.3.7. Strategy Overview
    - 21.3.3.7.1. Marketing Strategies
    - 21.3.3.7.2. Channel Strategies
- 21.3.4. Sanofi SA
  - 21.3.4.1. Overview
  - 21.3.4.2. Product Portfolio
  - 21.3.4.3. Sales Footprint
  - 21.3.4.4. Key Financial
  - 21.3.4.5. Key Developments
  - 21.3.4.6. SWOT Analysis
  - 21.3.4.7. Strategy Overview
    - 21.3.4.7.1. Marketing Strategies
    - 21.3.4.7.2. Channel Strategies
- 21.3.5. Exelixis Inc.
  - 21.3.5.1. Overview
  - 21.3.5.2. Product Portfolio
  - 21.3.5.3. Sales Footprint
  - 21.3.5.4. Key Financial
  - 21.3.5.5. Key Developments
  - 21.3.5.6. SWOT Analysis
  - 21.3.5.7. Strategy Overview
    - 21.3.5.7.1. Marketing Strategies
    - 21.3.5.7.2. Channel Strategies
- 21.3.6. Eisai Co. Ltd.
  - 21.3.6.1. Overview
  - 21.3.6.2. Product Portfolio
  - 21.3.6.3. Sales Footprint
  - 21.3.6.4. Key Financial
  - 21.3.6.5. Key Developments
  - 21.3.6.6. SWOT Analysis
  - 21.3.6.7. Strategy Overview
    - 21.3.6.7.1. Marketing Strategies
    - 21.3.6.7.2. Channel Strategies
- 21.3.7. Amgen Inc.
  - 21.3.7.1. Overview
  - 21.3.7.2. Product Portfolio
  - 21.3.7.3. Sales Footprint
  - 21.3.7.4. Key Financial
  - 21.3.7.5. Key Developments
  - 21.3.7.6. SWOT Analysis
  - 21.3.7.7. Strategy Overview
    - 21.3.7.7.1. Marketing Strategies
    - 21.3.7.7.2. Channel Strategies
- 21.3.8. F. Hoffmann-La Roche Ltd.
  - 21.3.8.1. Overview
  - 21.3.8.2. Product Portfolio
  - 21.3.8.3. Sales Footprint
  - 21.3.8.4. Key Financial
  - 21.3.8.5. Key Developments
  - 21.3.8.6. SWOT Analysis
  - 21.3.8.7. Strategy Overview
    - 21.3.8.7.1. Marketing Strategies
    - 21.3.8.7.2. Channel Strategies
- 21.3.9. Eli Lilly and Company
  - 21.3.9.1. Overview
  - 21.3.9.2. Product Portfolio
  - 21.3.9.3. Sales Footprint
  - 21.3.9.4. Key Financial
  - 21.3.9.5. Key Developments
  - 21.3.9.6. SWOT Analysis
  - 21.3.9.7. Strategy Overview
    - 21.3.9.7.1. Marketing Strategies
    - 21.3.9.7.2. Channel Strategies
- 21.3.10. Amneal Pharmaceuticals Inc.
  - 21.3.10.1. Overview
  - 21.3.10.2. Product Portfolio
  - 21.3.10.3. Sales Footprint
  - 21.3.10.4. Key Financial
  - 21.3.10.5. Key Developments
  - 21.3.10.6. SWOT Analysis
  - 21.3.10.7. Strategy Overview
    - 21.3.10.7.1. Marketing Strategies
    - 21.3.10.7.2. Channel Strategies
- 21.3.11. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  - 21.3.11.1. Overview
  - 21.3.11.2. Product Portfolio
  - 21.3.11.3. Sales Footprint
  - 21.3.11.4. Key Financial
  - 21.3.11.5. Key Developments
  - 21.3.11.6. SWOT Analysis
  - 21.3.11.7. Strategy Overview
    - 21.3.11.7.1. Marketing Strategies
    - 21.3.11.7.2. Channel Strategies
- 21.3.12. Takeda Pharmaceutical Co. Ltd.
  - 21.3.12.1. Overview
  - 21.3.12.2. Product Portfolio
  - 21.3.12.3. Sales Footprint
  - 21.3.12.4. Key Financial
  - 21.3.12.5. Key Developments
  - 21.3.12.6. SWOT Analysis
  - 21.3.12.7. Strategy Overview
    - 21.3.12.7.1. Marketing Strategies
    - 21.3.12.7.2. Channel Strategies
- 21.3.13. Sino Biopharma
  - 21.3.13.1. Overview
  - 21.3.13.2. Product Portfolio
  - 21.3.13.3. Sales Footprint
  - 21.3.13.4. Key Financial
  - 21.3.13.5. Key Developments
  - 21.3.13.6. SWOT Analysis
  - 21.3.13.7. Strategy Overview
    - 21.3.13.7.1. Marketing Strategies
    - 21.3.13.7.2. Channel Strategies
- 21.3.14. HUTCHMED
  - 21.3.14.1. Overview
  - 21.3.14.2. Product Portfolio
  - 21.3.14.3. Sales Footprint
  - 21.3.14.4. Key Financial
  - 21.3.14.5. Key Developments
  - 21.3.14.6. SWOT Analysis
  - 21.3.14.7. Strategy Overview
    - 21.3.14.7.1. Marketing Strategies
    - 21.3.14.7.2. Channel Strategies

22. Assumptions and Acronyms Used

23. Research Methodology

Product Code: PMRREP33422

List of Tables

Table 01: Global Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 02: Global Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 03: Global Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 04: Global Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 05: Global Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 06: Global Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 07: Global Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 08: Global Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 09: Global Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 10: Global Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel
Table 11: Global Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Region
Table 12: Global Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Region
Table 13: North America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 14: North America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Country
Table 15: North America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 16: North America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 17: North America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 18: North America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 19: North America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 20: North America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 21: North America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 22: North America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 23: North America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 24: North America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel
Table 25: Latin America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 26: Latin America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Country
Table 27: Latin America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 28: Latin America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 29: Latin America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 30: Latin America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 31: Latin America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 32: Latin America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 33: Latin America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 34: Latin America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 35: Latin America Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 36: Latin America Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel
Table 37: Europe Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 38: Europe Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Country
Table 39: Europe Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 40: Europe Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 41: Europe Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 42: Europe Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 43: Europe Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 44: Europe Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 45: Europe Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 46: Europe Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 47: Europe Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 48: Europe Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel
Table 49: East Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 50: East Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Country
Table 51: East Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 52: East Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 53: East Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 54: East Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 55: East Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 56: East Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 57: East Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 58: East Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 59: East Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 60: East Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel
Table 61: South Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 62: South Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Country
Table 63: South Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 64: South Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 65: South Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 66: South Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 67: South Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 68: South Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 69: South Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 70: South Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 71: South Asia Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 72: South Asia Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel
Table 73: Oceania Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 74: Oceania Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Country
Table 75: Oceania Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 76: Oceania Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 77: Oceania Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 78: Oceania Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 79: Oceania Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 80: Oceania Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 81: Oceania Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 82: Oceania Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 83: Oceania Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 84: Oceania Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel
Table 85: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 86: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Country
Table 87: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 88: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Drug Types
Table 89: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 90: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Drug Types
Table 91: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Types
Table 92: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Types
Table 93: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Disease Indication
Table 94: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Disease Indication
Table 95: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 96: Middle East & Africa Anti-VEGF Market Value (US$ Mn) Forecast 2023-2033, By Distribution Channel

List of Figures

Figure 01: Global Anti-VEGF Market Value, 2012-2022
Figure 02: Global Anti-VEGF Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032
Figure 03: Global Anti-VEGF Market Absolute $ Opportunity, 2022-2032
Figure 04: Global Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2032
Figure 05: Global Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 06: Global Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2032
Figure 07: Global Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 08: Global Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2032
Figure 09: Global Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 10: Global Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 11: Global Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2032
Figure 12: Global Anti-VEGF Market Share Analysis (%) by Region, 2022 & 2032
Figure 13: Global Anti-VEGF Market Attractiveness Analysis, By Region, 2023-2033
Figure 14: North America Anti-VEGF Market Value Share, By Country (2023 E)
Figure 15: North America Anti-VEGF Market Value Share, By Drug Type (2023 E)
Figure 16: North America Anti-VEGF Market Value Share, By Types (2023 E)
Figure 17: North America Anti-VEGF Market Value Share, By Disease Indication (2023 E)
Figure 18: North America Anti-VEGF Market Value Share, By Distribution Channel (2023 E)
Figure 19: North America Anti-VEGF Market Size (US$ Mn) Analysis, 2012-2022
Figure 20: North America Anti-VEGF Market Size (US$ Mn) & Y-o-Y Growth (%), 2023-2033
Figure 21: North America Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 22: North America Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 23: North America Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 24: North America Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 25: North America Anti-VEGF Market Attractiveness Analysis, By Country, 2023-2033
Figure 26: U.S. Market Value Proportion Analysis, 2022
Figure 27: U.S. Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 28: U.S. Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 29: U.S. Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 30: U.S. Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 31: Canada Market Value Proportion Analysis, 2022
Figure 32: Canada Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 33: Canada Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 34: Canada Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 35: Canada Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 36: Latin America Anti-VEGF Market Value Share, By Country (2023 E)
Figure 37: Latin America Anti-VEGF Market Value Share, By Drug Type (2023 E)
Figure 38: Latin America Anti-VEGF Market Value Share, By Types (2023 E)
Figure 39: Latin America Anti-VEGF Market Value Share, By Disease Indication (2023 E)
Figure 40: Latin America Anti-VEGF Market Value Share, By Distribution Channel (2023 E)
Figure 41: Latin America Anti-VEGF Market Size (US$ Mn) Analysis, 2012-2022
Figure 42: Latin America Anti-VEGF Market Size (US$ Mn) & Y-o-Y Growth (%), 2023-2033
Figure 43: Latin America Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 44: Latin America Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 45: Latin America Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 46: Latin America Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 47: Latin America Anti-VEGF Market Attractiveness Analysis, By Country, 2023-2033
Figure 48: Brazil Market Value Proportion Analysis, 2022
Figure 49: Brazil Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 50: Brazil Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 51: Brazil Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 52: Brazil Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 53: Mexico Market Value Proportion Analysis, 2022
Figure 54: Mexico Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 55: Mexico Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 56: Mexico Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 57: Mexico Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 58: Argentina Market Value Proportion Analysis, 2022
Figure 59: Argentina Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 60: Argentina Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 61: Argentina Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 62: Argentina Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 63: Europe Anti-VEGF Market Value Share, By Country (2023 E)
Figure 64: Europe Anti-VEGF Market Value Share, By Drug Type (2023 E)
Figure 65: Europe Anti-VEGF Market Value Share, By Types (2023 E)
Figure 66: Europe Anti-VEGF Market Value Share, By Disease Indication (2023 E)
Figure 67: Europe Anti-VEGF Market Value Share, By Distribution Channel (2023 E)
Figure 68: Europe Anti-VEGF Market Size (US$ Mn) Analysis, 2012-2022
Figure 69: Europe Anti-VEGF Market Size (US$ Mn) & Y-o-Y Growth (%), 2023-2033
Figure 70: Europe Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 71: Europe Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 72: Europe Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 73: Europe Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 74: Europe Anti-VEGF Market Attractiveness Analysis, By Country, 2023-2033
Figure 75: Germany Market Value Proportion Analysis, 2022
Figure 76: Germany Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 77: Germany Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 78: Germany Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 79: Germany Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 80: U.K. Market Value Proportion Analysis, 2022
Figure 81: U.K. Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 82: U.K. Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 83: U.K. Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 84: U.K. Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 85: Italy Market Value Proportion Analysis, 2022
Figure 86: Italy Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 87: Italy Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 88: Italy Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 89: Italy Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 90: France Market Value Proportion Analysis, 2022
Figure 91: France Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 92: France Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 93: France Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 94: France Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 95: Spain Market Value Proportion Analysis, 2022
Figure 96: Spain Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 97: Spain Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 98: Spain Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 99: Spain Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 100: Russia Market Value Proportion Analysis, 2022
Figure 101: Russia Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 102: Russia Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 103: Russia Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 104: Russia Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 105: Nordic Countries Market Value Proportion Analysis, 2022
Figure 106: Nordic Countries Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 107: Nordic Countries Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 108: Nordic Countries Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 109: Nordic Countries Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 110: BENULUX Market Value Proportion Analysis, 2022
Figure 111: BENULUX Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 112: BENULUX Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 113: BENULUX Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 114: BENULUX Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 115: East Asia Anti-VEGF Market Value Share, By Country (2023 E)
Figure 116: East Asia Anti-VEGF Market Value Share, By Drug Type (2023 E)
Figure 117: East Asia Anti-VEGF Market Value Share, By Types (2023 E)
Figure 118: East Asia Anti-VEGF Market Value Share, By Disease Indication (2023 E)
Figure 119: East Asia Anti-VEGF Market Value Share, By Distribution Channel (2023 E)
Figure 120: East Asia Anti-VEGF Market Size (US$ Mn) Analysis, 2012-2022
Figure 121: East Asia Anti-VEGF Market Size (US$ Mn) & Y-o-Y Growth (%), 2023-2033
Figure 122: East Asia Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 123: East Asia Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 124: East Asia Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 125: East Asia Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 126: East Asia Anti-VEGF Market Attractiveness Analysis, By Country, 2023-2033
Figure 127: China Market Value Proportion Analysis, 2022
Figure 128: China Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 129: China Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 130: China Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 131: China Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 132: Japan Market Value Proportion Analysis, 2022
Figure 133: Japan Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 134: Japan Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 135: Japan Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 136: Japan Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 137: South Korea Market Value Proportion Analysis, 2022
Figure 138: South Korea Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 139: South Korea Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 140: South Korea Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 141: South Korea Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 142: South Asia Anti-VEGF Market Value Share, By Country (2023 E)
Figure 143: South Asia Anti-VEGF Market Value Share, By Drug Type (2023 E)
Figure 144: South Asia Anti-VEGF Market Value Share, By Types (2023 E)
Figure 145: South Asia Anti-VEGF Market Value Share, By Disease Indication (2023 E)
Figure 146: South Asia Anti-VEGF Market Value Share, By Distribution Channel (2023 E)
Figure 147: South Asia Anti-VEGF Market Size (US$ Mn) Analysis, 2012-2022
Figure 148: South Asia Anti-VEGF Market Size (US$ Mn) & Y-o-Y Growth (%), 2023-2033
Figure 149: South Asia Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 150: South Asia Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 151: South Asia Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 152: South Asia Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 153: South Asia Anti-VEGF Market Attractiveness Analysis, By Country, 2023-2033
Figure 154: India Market Value Proportion Analysis, 2022
Figure 155: India Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 156: India Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 157: India Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 158: India Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 159: Thailand Market Value Proportion Analysis, 2022
Figure 160: Thailand Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 161: Thailand Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 162: Thailand Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 163: Thailand Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 164: Indonesia Market Value Proportion Analysis, 2022
Figure 165: Indonesia Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 166: Indonesia Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 167: Indonesia Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 168: Indonesia Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 169: Malaysia Market Value Proportion Analysis, 2022
Figure 170: Malaysia Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 171: Malaysia Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 172: Malaysia Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 173: Malaysia Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 174: Oceania Anti-VEGF Market Value Share, By Country (2023 E)
Figure 175: Oceania Anti-VEGF Market Value Share, By Drug Type (2023 E)
Figure 176: Oceania Anti-VEGF Market Value Share, By Types (2023 E)
Figure 177: Oceania Anti-VEGF Market Value Share, By Disease Indication (2023 E)
Figure 178: Oceania Anti-VEGF Market Value Share, By Distribution Channel (2023 E)
Figure 179: Oceania Anti-VEGF Market Size (US$ Mn) Analysis, 2012-2022
Figure 180: Oceania Anti-VEGF Market Size (US$ Mn) & Y-o-Y Growth (%), 2023-2033
Figure 181: Oceania Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 182: Oceania Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 183: Oceania Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 184: Oceania Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 185: Oceania Anti-VEGF Market Attractiveness Analysis, By Country, 2023-2033
Figure 186: Australia Market Value Proportion Analysis, 2022
Figure 187: Australia Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 188: Australia Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 189: Australia Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 190: Australia Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 191: New Zealand Market Value Proportion Analysis, 2022
Figure 192: New Zealand Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 193: New Zealand Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 194: New Zealand Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 195: New Zealand Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 196: Middle East & Africa Anti-VEGF Market Value Share, By Country (2023 E)
Figure 197: Middle East & Africa Anti-VEGF Market Value Share, By Drug Type (2023 E)
Figure 198: Middle East & Africa Anti-VEGF Market Value Share, By Types (2023 E)
Figure 199: Middle East & Africa Anti-VEGF Market Value Share, By Disease Indication (2023 E)
Figure 200: Middle East & Africa Anti-VEGF Market Value Share, By Distribution Channel (2023 E)
Figure 201: Middle East & Africa Anti-VEGF Market Size (US$ Mn) Analysis, 2012-2022
Figure 202: Middle East & Africa Anti-VEGF Market Size (US$ Mn) & Y-o-Y Growth (%), 2023-2033
Figure 203: Middle East & Africa Anti-VEGF Market Attractiveness Analysis, By Drug Types, 2023-2033
Figure 204: Middle East & Africa Anti-VEGF Market Attractiveness Analysis, By Types, 2023-2033
Figure 205: Middle East & Africa Anti-VEGF Market Attractiveness Analysis, By Disease Indication, 2023-2033
Figure 206: Middle East & Africa Anti-VEGF Market Attractiveness Analysis, By Distribution Channel, 2023-2033
Figure 207: Middle East & Africa Anti-VEGF Market Attractiveness Analysis, By Country, 2023-2033
Figure 208: GCC Countries Market Value Proportion Analysis, 2022
Figure 209: GCC Countries Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 210: GCC Countries Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 211: GCC Countries Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 212: GCC Countries Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 213: Turkiye Market Value Proportion Analysis, 2022
Figure 214: Turkiye Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 215: Turkiye Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 216: Turkiye Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 217: Turkiye Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 218: North Africa Market Value Proportion Analysis, 2022
Figure 219: North Africa Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 220: North Africa Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 221: North Africa Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 222: North Africa Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 223: South Africa Market Value Proportion Analysis, 2022
Figure 224: South Africa Anti-VEGF Market Share Analysis (%) by Drug Types, 2022 & 2033
Figure 225: South Africa Anti-VEGF Market Share Analysis (%) by Types, 2022 & 2033
Figure 226: South Africa Anti-VEGF Market Share Analysis (%) by Disease Indication, 2022 & 2033
Figure 227: South Africa Anti-VEGF Market Share Analysis (%) by Distribution Channel, 2022 & 2033

Market Study on Anti-VEGF: Close to Half of the Market Share Accounted for by Vascular Endothelial Growth Factor-A inhibitors

Description

Table of Contents

List of Tables

Key Market Segments

Key Questions Answered in Report

Research Methodology

Table of Contents

1. Executive Summary

2. Market Overview

3. Key Market Trends

4. Key Success Factors

5. Market Background

6. COVID-19 Crisis Analysis

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012-2022 and Forecast, 2023-2033

8. Global Market Analysis 2012-2022 and Forecast 2023-2033, By Drug Types

9. Global Market Analysis 2012-2022 and Forecast 2023-2033, By Types

10. Global Market Analysis 2012-2022 and Forecast 2023-2033, By Disease Indication

11. Global Market Analysis 2012-2022 and Forecast 2023-2033, By Distribution Channel

12. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Region

13. North America Market Analysis 2012-2022 and Forecast 2023-2033

14. Latin America Market Analysis 2012-2022 and Forecast 2023-2033

15. Europe Market Analysis 2012-2022 and Forecast 2023-2033

16. East Asia Market Analysis 2012-2022 and Forecast 2023-2033

17. South Asia Market Analysis 2012-2022 and Forecast 2023-2033

18. Oceania Market 2012-2022 and Forecast 2023-2033

19. Middle East and Africa (MEA) Market Analysis 2012-2022 and Forecast 2023-2033

20. Market Structure Analysis

21. Competition Analysis

22. Assumptions and Acronyms Used

23. Research Methodology

List of Tables

List of Figures